Liquidia Corp(LQDA) - 2025 Q3 - Earnings Call Presentation

YUTREPIA Adoption and Usage - Over 600 physicians are prescribing YUTREPIA [4] - More than 2,000 unique patient prescriptions have been written for YUTREPIA [4] - Over 1,500 patients have started on YUTREPIA [4] - Approximately 75% of patients starting YUTREPIA are new to treprostinil [5] - Around 10% of PAH prescriptions represent switches from oral therapies [5] Financial Performance - Liquidia Corporation's ending cash and cash equivalents for 3Q 2025 were $157.5 million [6] - Net product sales for 3Q 2025 were $51.669 million [6] - Total revenue for 3Q 2025 was $54.342 million [6] - Operating income for 3Q 2025 was $1.767 million [6] - Adjusted EBITDA for 3Q 2025 was $10.142 million [13]